How does the stock price jump $14.00 ps on Vyvanse earnings growth for q3 but our nationwide quota attainment is under 100%?? "Revenue for the company’s top selling drug, Vyvanse for attention deficit hyperactivity disorder, increased 21 percent to $299 million."
Because the company gets paid on total sales regardless of who writes the product, there is no "scrubbing" of the data. We get paid on "scrubbed" data where they take out scripts based on non-approved use and/or non-approved specialties. Which means one of two things: 1. Shire is selling a lot of product for non-approved use 2. the "scrubbed" data is short changing the true efforts of the sales force
Concern about non approved use of ADHD and similar drugs by executives, students and there has already cropped up in the media a few times, could be a big factor to watch in the future
